Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans

Hepatology

Volumn 31, Issue 5, 2000, Pages 1165-1175

  Korba, Brent E ^a   Cote, Paul ^a   Hornbuckle, William ^b   Tennant, Bud C ^b   Gerin, John L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b Department of Population Medicine and Diagnostic Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE 5' ARABINOSIDE MONOPHOSPHATE; FAMCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; RIBAVIRIN; UNCLASSIFIED DRUG; VIDARABINE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; VIREMIA; VIRUS REPLICATION; WOODCHUCK;

EID: 0034011592     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/he.2000.5982     Document Type: Article

References (11)

1. Gerin JL. Experimental WHV infection of woodchucks: an animal model of hepadnavirus-induced liver cancer. Gastroenterol Jpn 1990;25(Supp 1):38-42.
2. Tennant B, Gerin J. The woodchuck model of hepatitis B infection. In: Arias I, Boyer J, Fausto N, Jacoby W, Schachter D, Shafritz D, eds. The Liver: Biology-and Pathobiology. New York: Raven, 1994:1455-1-466.
3. Tencza MG, et al. Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. J Med Virol 1997;51:6-16.
4. Korba BE, Xie H, Wright KN, Hornbuckle WE, Gerin JL. Liver-targeted antiviral nucleosides: enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo. HEPATOLOGY 1996;23:958-963.
5. Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, Tochkov IA, et al. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. HEPATOLOGY 1998;28:179-191.
6. Tennant B, Baldwin B, Hornbuckle W, Korba B, Cote P, Gerin J. Animal models in the preclinical assessment of therapy for viral hepatitis. Antiviral Ther 1997;1:47-52.
7. Tennant B, Korba B, Cote P, Baldwin B, Graham L, Hornbuckle W, Gerin J. The woodchuck model in antiviral drug development. In: Rizzetto M, Purcell R, Gerin J, Verme G, eds. Viral Hepatitis and Liver Disease. Torino, Italy: Edizioni Minerva Medica SPA, 1997:754-757.
8. Tennant B, Peek S, Tochkov I, Baldwin B, Hornbuckle W, Korba B, Cote P, Gerin J. The woodchuck in preclinical assessement of therapy for hepatitis B infection. In: Schinazi R, Sommadossi J, Thomas H, eds. Therapies for Viral Hepatitis. New York: International Medical Press, 1998:171-176.
9. Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS, Tennant B, et al. Lamivudine therapy of WHV-infected woodchucks. Virology 1998;245:18-32.
10. Hurwitz S, Tennant B, Korba B, Gerin J, Schinazi R. Viral pharmacodynamics of (-)-β-2′,3′-dideoxy-3′-thiacytidine in chronically infected woodchucks compared to humans. Antimicrob Agents Chemother 1998;42:2804-2809.
11. Block TM, Lu X, Mehta AS, Blumberg BS, Tennant B, Ebling M, Korba B, et al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 1998;4:610-614.